Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules

Haematologica

Volumn 85, Issue 10 SUPPL., 2000, Pages 26-30

  Lollar, P ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; EPITOPE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIGENICITY; CONFERENCE PAPER; EPITOPE MAPPING; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; NONHUMAN; PROTEIN DOMAIN;

ANIMALS; EPITOPE MAPPING; EPITOPES; FACTOR VIII; HUMANS; RECOMBINANT FUSION PROTEINS; SWINE;

EID: 0033694552     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Kogenate previously untreated patient study group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and the development of inhibitors
2. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli
3. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments
4. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization
5. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies which bind to A2
6. Elimination of a major inhibitor epitope in factor VIII
7. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII
8. Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand
9. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis
10. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII
11. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine
12. A role for the C2 domain of factor binding to yon Willebrand factor
13. Membrane-binding peptide from the C2 domain of factor VIII forms an amphipathic structure as determined by NMR spectroscopy
14. Fukui. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
15. Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A)
16. Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity
17. Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor
18. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain
19. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX
20. Some human inhibitor antibodies interfere with factor VIII binding to factor IX
21. Reduction of the antigenicity of factor VIII toward complex inhibitory plasmas using multiply-substituted hybrid human/porcine factor VIII molecules
22. Use of porcine factor VIII in the treatment of patients with acquired hemophilia
23. Inhibitors in congenital haemophilia
24. Porcine factor VIII therapy in patients with factor VIII inhibitors
25. Immunoblot crossreactivity of factor VIII inhibitors with porcine factor VIII